NO20063279L - Methods and compositions for the treatment of lipodystrophy - Google Patents
Methods and compositions for the treatment of lipodystrophyInfo
- Publication number
- NO20063279L NO20063279L NO20063279A NO20063279A NO20063279L NO 20063279 L NO20063279 L NO 20063279L NO 20063279 A NO20063279 A NO 20063279A NO 20063279 A NO20063279 A NO 20063279A NO 20063279 L NO20063279 L NO 20063279L
- Authority
- NO
- Norway
- Prior art keywords
- lipodystrophy
- treatment
- methods
- compositions
- hiv
- Prior art date
Links
- 206010049287 Lipodystrophy acquired Diseases 0.000 title abstract 4
- 208000006132 lipodystrophy Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår fremgangsmåter og sammensetninger for behandlingen av lipodystrofi. Fremgangsmåtene kan brukes for behandling av lipodystrofi både hos HIV og ikke-HIV pasienter. Mer spesifikt angår fremgangsmåtene en kombinasjonsterapi som bruker veksthormon og statiner for å få tilveiebrakt en behandling av lipodystrofi.The present invention relates to methods and compositions for the treatment of lipodystrophy. The procedures can be used to treat lipodystrophy in both HIV and non-HIV patients. More specifically, the methods relate to combination therapy that uses growth hormone and statins to provide a treatment for lipodystrophy.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54020404P | 2004-01-29 | 2004-01-29 | |
US54336604P | 2004-02-10 | 2004-02-10 | |
PCT/EP2005/000758 WO2005074916A1 (en) | 2004-01-29 | 2005-01-26 | Methods and compositions for the treatment of lipodystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063279L true NO20063279L (en) | 2006-09-19 |
Family
ID=34841102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063279A NO20063279L (en) | 2004-01-29 | 2006-07-14 | Methods and compositions for the treatment of lipodystrophy |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1722778A1 (en) |
JP (1) | JP2007519669A (en) |
KR (1) | KR20060127977A (en) |
AU (1) | AU2005210093A1 (en) |
BR (1) | BRPI0507302A (en) |
CA (1) | CA2552404A1 (en) |
EA (1) | EA200601392A1 (en) |
IL (1) | IL176762A0 (en) |
NO (1) | NO20063279L (en) |
WO (1) | WO2005074916A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2903312B1 (en) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT |
JP5570999B2 (en) * | 2008-01-03 | 2014-08-13 | ユニベルシテ デ―マルセイユ | Composition for use in anti-HIV therapy |
WO2010121352A1 (en) * | 2009-04-20 | 2010-10-28 | Theratechnologies Inc. | Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy |
EP3125921B1 (en) * | 2014-03-11 | 2020-07-08 | Novartis AG | Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9803623D0 (en) * | 1998-10-22 | 1998-10-22 | Sahltech Ab | New therapeutic application |
-
2005
- 2005-01-26 WO PCT/EP2005/000758 patent/WO2005074916A1/en active Application Filing
- 2005-01-26 KR KR1020067016376A patent/KR20060127977A/en not_active Application Discontinuation
- 2005-01-26 AU AU2005210093A patent/AU2005210093A1/en not_active Abandoned
- 2005-01-26 JP JP2006550092A patent/JP2007519669A/en active Pending
- 2005-01-26 EA EA200601392A patent/EA200601392A1/en unknown
- 2005-01-26 BR BRPI0507302-2A patent/BRPI0507302A/en not_active IP Right Cessation
- 2005-01-26 EP EP05707019A patent/EP1722778A1/en not_active Withdrawn
- 2005-01-26 CA CA002552404A patent/CA2552404A1/en not_active Abandoned
-
2006
- 2006-07-10 IL IL176762A patent/IL176762A0/en unknown
- 2006-07-14 NO NO20063279A patent/NO20063279L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20060127977A (en) | 2006-12-13 |
WO2005074916A1 (en) | 2005-08-18 |
EA200601392A1 (en) | 2006-12-29 |
IL176762A0 (en) | 2006-10-31 |
BRPI0507302A (en) | 2007-06-26 |
JP2007519669A (en) | 2007-07-19 |
EP1722778A1 (en) | 2006-11-22 |
AU2005210093A1 (en) | 2005-08-18 |
CA2552404A1 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006068729A3 (en) | Methods and compositions for enhancing iron absorption | |
WO2008030505A8 (en) | Methods and compositions for the treatment of antibody mediated neuropathies | |
WO2009115652A3 (en) | Bitherapy and tritherapy used for treating an hiv-positive patient | |
WO2009044173A3 (en) | Methods of treating cancer using notch pathway inhibitors | |
MX2009013349A (en) | Chemical compounds. | |
MX2009004038A (en) | Diclofenac gel. | |
MX2007003095A (en) | Methods and devices for the non-thermal, electrically-induced closure of blood vessels. | |
WO2007120626A3 (en) | Uses and compositions for treatment of ankylosing spondylitis | |
ATE499109T1 (en) | PROTEAsome INHIBITION COMPOSITION | |
WO2005117870A3 (en) | Combination of proton pump inhibitor, buffering agent, and prokinetic agent | |
UA88463C2 (en) | Pharmaceutical composition comprising compound i and method of treating hiv infection | |
DE602005026866D1 (en) | USE OF THREE-DIMENSIONAL CULTURED TISSUE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | |
NO20075304L (en) | Method of decreasing calcification | |
EP1670450B8 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
NO20054371L (en) | Somatostatin-dopamine chimeric analogs | |
TW200716224A (en) | Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy | |
MX350046B (en) | Treatments for gastrointestinal disorders. | |
WO2008118849A3 (en) | Hiv-1 protease inhibitors | |
ATE541848T1 (en) | DIARYL-PURINE, AZAPURINE AND DEAZAPURINE AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV | |
MX2022001004A (en) | Enzyme inhibitors. | |
TW200716088A (en) | Formulations and methods for treating amyloidosis | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
NO20075764L (en) | Combined use of prostaglandin compound and proton pump inhibitor to treat gastrointestinal disorders | |
NO20063279L (en) | Methods and compositions for the treatment of lipodystrophy | |
MX2009011930A (en) | Combination therapy for the treatment of hcv infection. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |